Aug 20 (Reuters) - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the...
** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year
(Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...
(Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...
We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
value estimate in place following Amicus Therapeutics ' FOLD third-quarter results, despite ..... In conjunction with earnings, Amicus announced the termination of ..... clinical-stage drug candidates. Amicus regains international rights
Amicus Therapeutics FOLD announced Oct. 2 that Plicera has failed ..... meaningful improvement, and though Amicus expects to conduct a detailed analysis ..... safety is an overarching concern for Amicus ' technology (there is no evidence
Amicus Therapeutics FOLD reported another quarter in the red ..... regarding the design of the trial. Amicus ' second oral rare-disease treatment ..... Phase II data in the third quarter. Amicus and Shire are poised to move aggressively
Amicus Therapeutics FOLD has made substantial progress in its ..... maintaining our fair value estimate for now. Amicus has completed post-Phase II meetings ..... expenses to grow significantly in 2009, as Amicus and international partner Shire SHPGY
new Fabrazyme patients to Phase II trials of oral Fabry disease candidate Amigal, developed by private biotech Amicus Therapeutics . Key data comparing Fabrazyme with Replagal should be available by the end of 2006. Countering this change